The mitochondrial regulator PGC1α is induced by cGMP–PKG signaling and mediates the protective effects of phosphodiesterase 5 inhibition in heart failure

Phosphodiesterase 5 inhibition (PDE5i) activates cGMP‐dependent protein kinase (PKG) and ameliorates heart failure; however, its impact on cardiac mitochondrial regulation has not been fully determined. Here, we investigated the role of the mitochondrial regulator peroxisome proliferator‐activated receptor γ co‐activator‐1α (PGC1α) in the PDE5i‐conferred cardioprotection, utilizing PGC1α null mice. In PGC1α+/+ hearts exposed to 7 weeks of pressure overload by transverse aortic constriction, chronic treatment with the PDE5 inhibitor sildenafil improved cardiac function and remodeling, with improved mitochondrial respiration and upregulation of PGC1α mRNA in the myocardium. By contrast, PDE5i‐elicited benefits were abrogated in PGC1α−/− hearts. In cultured cardiomyocytes, PKG overexpression induced PGC1α, while inhibition of the transcription factor CREB abrogated the PGC1α induction. Together, these results suggest that the PKG–PGC1α axis plays a pivotal role in the therapeutic efficacy of PDE5i in heart failure.

[1]  Jian-mei Gao,et al.  Icariside II, a PDE5 Inhibitor, Suppresses Oxygen-Glucose Deprivation/Reperfusion-Induced Primary Hippocampal Neuronal Death Through Activating the PKG/CREB/BDNF/TrkB Signaling Pathway , 2020, Frontiers in Pharmacology.

[2]  P. Ponikowski,et al.  Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. , 2020, The New England journal of medicine.

[3]  Dong Ik Lee,et al.  PKG-Modified TSC2 Regulates mTORC1 Activity to Counter Adverse Cardiac Stress , 2018, Nature.

[4]  D. Kass,et al.  Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G. , 2016, Cardiovascular research.

[5]  G. Dorn,et al.  Mitochondrial Function, Biology, and Role in Disease: A Scientific Statement From the American Heart Association. , 2016, Circulation research.

[6]  V. Thu,et al.  NecroX-5 protects mitochondrial oxidative phosphorylation capacity and preserves PGC1α expression levels during hypoxia/reoxygenation injury , 2016, The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology.

[7]  Sanjiv J. Shah,et al.  Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. , 2015, JAMA.

[8]  Dong I. Lee,et al.  Prevention of PKG1α oxidation augments cardioprotection in the stressed heart. , 2015, The Journal of clinical investigation.

[9]  Thomas Danner,et al.  Phosphodiesterase 9A Controls Nitric-oxide Independent cGMP and Hypertrophic Heart Disease , 2015, Nature.

[10]  R. Tian,et al.  Promoting PGC-1α-driven mitochondrial biogenesis is detrimental in pressure-overloaded mouse hearts. , 2014, American journal of physiology. Heart and circulatory physiology.

[11]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[12]  D. Kass,et al.  Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. , 2014, Circulation research.

[13]  Dong I. Lee,et al.  PDE5 inhibitor efficacy is estrogen dependent in female heart disease. , 2014, The Journal of clinical investigation.

[14]  Stephen T. C. Wong,et al.  Mechanical Unloading Promotes Myocardial Energy Recovery in Human Heart Failure , 2014, Circulation. Cardiovascular genetics.

[15]  Saisudha Koka,et al.  Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO/SIRT1/PGC-1α signaling. , 2014, American journal of physiology. Heart and circulatory physiology.

[16]  S. Solomon,et al.  The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction , 2013, Journal of the American Heart Association.

[17]  D. Kass,et al.  Protein Kinase G Positively Regulates Proteasome-Mediated Degradation of Misfolded Proteins , 2013, Circulation.

[18]  Manesh R. Patel,et al.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.

[19]  M. Gheorghiade,et al.  Mitochondria as a therapeutic target in heart failure. , 2013, Journal of the American College of Cardiology.

[20]  J. Jordan,et al.  Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. , 2012, Journal of Clinical Investigation.

[21]  G. Ailhaud,et al.  Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. , 2012, The Journal of clinical investigation.

[22]  Z. Arany,et al.  PGC-1 coactivators in the cardiovascular system , 2012, Trends in Endocrinology & Metabolism.

[23]  E. Takimoto.  Cyclic GMP-dependent signaling in cardiac myocytes. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[24]  D. Kelly,et al.  The PGC-1 cascade as a therapeutic target for heart failure. , 2011, Journal of molecular and cellular cardiology.

[25]  R. Arena,et al.  PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure: Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study , 2011, Circulation. Heart failure.

[26]  R. Arena,et al.  PDE 5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function , Cardiac Geometry , and Clinical Status in Patients With Stable Systolic Heart Failure , 2011 .

[27]  D. Kass,et al.  Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE 5 inhibition in mice , 2009 .

[28]  D. Kass,et al.  Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. , 2008, Cellular signalling.

[29]  Xianlin Han,et al.  The transcriptional coactivator PGC-1alpha is essential for maximal and efficient cardiac mitochondrial fatty acid oxidation and lipid homeostasis. , 2008, American journal of physiology. Heart and circulatory physiology.

[30]  C. Long,et al.  Restoration of CREB function is linked to completion and stabilization of adaptive cardiac hypertrophy in response to exercise. , 2007, American journal of physiology. Heart and circulatory physiology.

[31]  H. Mukuno,et al.  cAMP-responsive element binding protein mediates a cGMP/protein kinase G-dependent anti-apoptotic signal induced by nitric oxide in retinal neuro-glial progenitor cells. , 2007, Experimental Eye Research.

[32]  B. Spiegelman,et al.  Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1alpha. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[33]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[34]  U. Moens,et al.  What turns CREB on? , 2004, Cellular signalling.

[35]  Marc Montminy,et al.  PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3. , 2004, Nature medicine.

[36]  E. Clementi,et al.  Mitochondrial Biogenesis in Mammals: The Role of Endogenous Nitric Oxide , 2003, Science.

[37]  J. Saffitz,et al.  Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. , 2000, The Journal of clinical investigation.

[38]  Jesse D. Roberts,et al.  Adenovirus-mediated Gene Transfer of cGMP-dependent Protein Kinase Increases the Sensitivity of Cultured Vascular Smooth Muscle Cells to the Antiproliferative and Pro-apoptotic Effects of Nitric Oxide/cGMP* , 1998, The Journal of Biological Chemistry.